LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma

Table 1 Relationship between MYLK-AS1 and clinicopathological parameters in 156 HCC patients

Clinical variables	Number of cases	MYLK-AS1 expression		P value
Clinical variables	Number of cases	Low N = 78	High N = 78	P value
Age (years)
> 50	26	15	11	0.390
≤ 50	130	63	67
Gender
Male	103	48	55	0.237
Female	53	30	23
Tumor number
Single	125	65	60	0.316
Multiple	31	13	18
Etiology
viral	122	58	64
Non-viral	34	20	14	0.245
Serum AFP (ng/ml)
≤ 200	75	33	42	0.149
> 200	81	45	36
Tumor stage
I/II	85	52	33	0.002
III/IV	71	26	45
Tumor size (cm)
≤ 5	62	41	21	0.001
> 5	94	37	57
Tumor differentiation
Well	58	37	21	0.018
Moderate	49	23	26
Poor	49	18	31
Vascular invasion
Yes	50	19	31	0.040
No	106	59	47
TACE treatment
Yes	72	28	44	0.010
No	84	50	34

ISSN: 1756-9966